ArticleJMIR research protocols2026
Efficacy and Safety of Kanggan Mixture for Influenza: Protocol for a Multicenter Open-Label Randomized Controlled Trial.
Article in JMIR research protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInfluenza, a highly contagious acute respiratory illness, causes annual seasonal epidemics worldwide, imposing a substantial public health burden. Although neuraminidase inhibitors, such as oseltamivir, can shorten symptom duration, their use is limited by antiviral resistance and adverse reactions. Kanggan mixture (KGM), an in-hospital traditional Chinese medicine preparation at Jiangsu Province Hospital of Chinese Medicine, has been widely used in clinical practice for influenza treatment, showing favorable effects on fever reduction and symptom improvement; however, high-quality comparative evidence on the efficacy and safety of KGM remains limited. This study is designed to address this gap by evaluating whether KGM is noninferior to oseltamivir for the treatment of influenza.
objectiveThis study aims to determine whether KGM is noninferior to oseltamivir in improving the clinical outcomes in patients with influenza and to assess the safety profile of KGM.
methodsThis study is a multicenter, open-label, randomized controlled trial to be conducted in 3 tertiary grade A hospitals in China. Eligible participants with influenza will be randomly assigned in a 1:1 ratio to receive either KGM or oseltamivir for 5 days. A total of 184 participants will be enrolled, with 92 (50%) participants in each group. The primary outcome is time to clinical alleviation. Secondary outcomes include time to defervescence, time to onset of antipyretic effect, individual influenza symptom scores, and total influenza symptom scores. Adverse events will be monitored throughout the trial to evaluate the safety of KGM.
resultsThis study was funded in July 2024. Recruitment began in September 2025 and is expected to be completed in June 2026. The study results are expected to be published by December 2026.
conclusionsThis protocol describes a multicenter randomized controlled trial designed to generate comparative evidence on the efficacy and safety of KGM for influenza treatment. The findings of this study are expected to provide initial clinical evidence supporting the use of KGM in the treatment of influenza, clarify its therapeutic value as a potential alternative to oseltamivir, and offer a novel alternative strategy for influenza management while contributing to the evidence base for integrating traditional Chinese medicine into influenza care.
trial registrationInternational Traditional Medicine Clinical Trial Registry ITMCTR2025000743; https://itmctr.ccebtcm.org.cn/mgt/project/view/-5368318132552339899. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/89891.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.